cusatuzumab
Small moleculeexperimental
Clinical trial activity
8 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2013 (NCT01813539)
Timeline
Indications
Mechanism of action
- CD70 antigenINHIBITOR
CD70 inhibitor
- Unspecified targetADCC
adcc
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297891 ↗
Also known as
- argx-110
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06384261 | Phase 2 | Jul 22, 2024 | OncoVerity, Inc. |
| NCT04264806 | Phase 2 | Apr 1, 2020 | argenx, Janssen Pharmaceutica NV |
| NCT04241549 | Phase 1 | Mar 31, 2020 | argenx, Janssen Pharmaceutica NV |
| NCT04150887 | Phase 1 | Dec 16, 2019 | argenx, Janssen Pharmaceutica NV |
| NCT04023526 | Phase 2 | Jul 24, 2019 | argenx, Janssen Pharmaceutica NV |
| NCT03030612 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2016 | argenx |
| NCT02759250 | Phase 1 | Feb 1, 2015 | argenx, Universitair Ziekenhuis Gent |
| NCT01813539 | Phase 1 | Feb 1, 2013 | argenx, Free University of Brussels |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| argenx | For profit | 7 | 3 | 2 | 2013 |
| Janssen Pharmaceutica NV | For profit | 4 | 4 | 2 | 2019 |
| Free University of Brussels | Academic/Hospital | 1 | 0 | 1 | 2013 |
| OncoVerity, Inc. | For profit | 1 | 1 | 1 | 2024 |
| Universitair Ziekenhuis Gent | Academic/Hospital | 1 | 0 | 1 | 2015 |
5 organizations
Page 1 / 1